Patents by Inventor Debra D. Donaldson
Debra D. Donaldson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8221752Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: GrantFiled: October 8, 2009Date of Patent: July 17, 2012Assignee: Wyeth LLCInventors: Marion T. Kasaian, Lioudmila Gennadievna Tchistiakova, Geertruida Machteld Veldman, Kimberly Ann Marquette, Xiang-Yang Tan, Debra D. Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L. Wood, Lori J. Fitz, Angela M. Widom, Kevin D. Parris, Samuel J. Goldman, Jose W. Saldanha
-
Publication number: 20110262435Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: ApplicationFiled: May 2, 2011Publication date: October 27, 2011Applicant: Wyeth LLCInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Patent number: 7994292Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins, antibodies (and fragments thereof) that specifically bind to MU-1 proteins (and fragments thereof), and methods for their production are also disclosed.Type: GrantFiled: January 28, 2010Date of Patent: August 9, 2011Assignee: Genetics Institute, LLCInventors: Debra D. Donaldson, Michelle J. Unger
-
Patent number: 7943342Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: GrantFiled: January 22, 2009Date of Patent: May 17, 2011Assignee: Wyeth LLCInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Publication number: 20100130729Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins, antibodies (and fragments thereof) that specifically bind to MU-1 proteins (and fragments thereof), and methods for their production are also disclosed.Type: ApplicationFiled: January 28, 2010Publication date: May 27, 2010Inventors: Debra D. Donaldson, Michelle J. Unger
-
Publication number: 20100129360Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: ApplicationFiled: October 8, 2009Publication date: May 27, 2010Applicant: WYETH LLCInventors: Marion T. Kasaian, Lioudmila Gennadievna Tchistiakova, Geertruida Machteld Veldman, Kimberly Ann Marquette, Xiang-Yang Tan, Debra D. Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L. Wood, Lori J. Fitz, Angela M. Widom, Kevin D. Parris, Samuel J. Goldman, Jose W. Saldanha
-
Patent number: 7705123Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.Type: GrantFiled: December 17, 2007Date of Patent: April 27, 2010Assignee: Genetics Institute, LLCInventors: Debra D. Donaldson, Michelle J. Unger
-
Patent number: 7615213Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: GrantFiled: June 9, 2005Date of Patent: November 10, 2009Assignee: WyethInventors: Marion T. Kasaian, Lioudmila Tchistiakova, Geertruida M. Veldman, Kimberly Ann Marquette, Xiang-Yang Tan, Debra D. Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L. Wood, Lori J. Fitz, Angela M. Widom, Kevin D. Parris, Samuel J. Goldman, Jose W. Saldanha
-
Publication number: 20090274705Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: ApplicationFiled: January 22, 2009Publication date: November 5, 2009Applicant: WYETHInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Publication number: 20090214516Abstract: Methods of screening for agents for treating asthma are provided. The methods involve screening for agents that decrease the production or activity of a RegIII protein that has been discovered herein to play a role in producing the symptoms and pathological complications involved in asthma. Methods of treating asthma, as well as screening for and treating with inhibitors of a RegIII protein are also provided.Type: ApplicationFiled: June 3, 2005Publication date: August 27, 2009Inventors: Maximillian T. Follettie, Debra D. Donaldson
-
Patent number: 7501121Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: GrantFiled: June 17, 2005Date of Patent: March 10, 2009Assignee: WyethInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Publication number: 20080167241Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.Type: ApplicationFiled: December 17, 2007Publication date: July 10, 2008Applicant: GENETICS INSTITUTE, LLCInventors: Debra D. Donaldson, Michelle J. Unger
-
Publication number: 20080076120Abstract: The present invention is directed to the identification of predictive genotypes, e.g., predictive single nucleotide polymorphisms (SNPs), and markers that can be used to determine whether a patient having a CC-Chemokine Receptor 2 (CCR-2) mediated disorders is likely to be responsive or non-responsive to a therapeutic regimen. For example, the present invention is directed, in part, to the use of certain individual and/or combinations of SNPs, wherein the expression of particular alleles at particular SNPs, or combinations of alleles at loci in linkage disequilibrium with a particular SNP, correlate with responsiveness or non-responsiveness to a therapeutic regimen. The present invention is also directed to the use of certain individual and/or combinations of predictive markers which correlate with responsiveness or non-responsiveness to a therapeutic regimen.Type: ApplicationFiled: September 14, 2006Publication date: March 27, 2008Inventors: Debra D. Donaldson, Alexander N. Parker
-
Patent number: 7198789Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.Type: GrantFiled: October 4, 2002Date of Patent: April 3, 2007Assignee: Genetics Institute, LLCInventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger
-
Patent number: 7189400Abstract: Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein.Type: GrantFiled: October 4, 2001Date of Patent: March 13, 2007Assignee: Genetics Institute, LLCInventors: Laura Carter, Matthew J. Whitters, Mary Collins, Deborah A. Young, Debra D. Donaldson, Lesile D. Lowe, Michelle Unger
-
Publication number: 20030108549Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.Type: ApplicationFiled: October 4, 2002Publication date: June 12, 2003Applicant: WyethInventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger
-
Publication number: 20030049798Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.Type: ApplicationFiled: October 4, 2001Publication date: March 13, 2003Inventors: Laura Carter, Matthew J. Whitters, Mary Collins, Deborah A. Young, Debra D. Donaldson, Leslie D. Lowe, Michelle Unger
-
Patent number: 6057128Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.Type: GrantFiled: March 17, 1998Date of Patent: May 2, 2000Assignee: Genetics Institute, Inc.Inventors: Debra D. Donaldson, Michelle Unger
-
Patent number: 5674841Abstract: The present invention discloses a method for protecting cycling or dividing stem cells from the cytotoxic effects of chemotherapeutic agents and radiation by administering prior to exposure to these agents, an effective amount of Stem Cell Inhibitory Factor as well as a composition useful therefore.Type: GrantFiled: April 21, 1994Date of Patent: October 7, 1997Assignee: Genetics Institute, Inc.Inventors: Ian B. Pragnell, Debra D. Donaldson, Gerald J. Graham, Gordon G. Wong